Saturday, October 16News That Matters
Shadow

Tag: depression

CDC: Depression, anxiety continue rise in U.S. due to COVID-19 pandemic

CDC: Depression, anxiety continue rise in U.S. due to COVID-19 pandemic

Health
March 26 (UPI) -- More than 40% of adults in the United States experienced symptoms of anxiety or depressive disorders at some point between August 2020 and the end of January, according to data released Friday by the Centers for Disease Control and Prevention. Over the roughly six-month period, the percentage of adults reporting symptoms of these disorders nationally increased from to 42% from 36%, roughly a 17% jump, the data showed. Advertisement The percentage of adults across the country who took a prescription for one of these disorders during this time rose to 25% from 22%. As of the end of January, 12% of adults of all ages nationally indicated that they needed mental health treatment, but did not receive it, up from 9% in early August. The trends are likely linked with the ongoi...
Study: 33% of U.S. adults suffer from anxiety, depression related to COVID-19 pandemic

Study: 33% of U.S. adults suffer from anxiety, depression related to COVID-19 pandemic

Health
Feb. 19 (UPI) -- One-third of adults in the United States report experiencing symptoms of anxiety or depression as a result of the COVID-19 pandemic, a study published Friday by JAMA Network Open found. In addition, 30% said they suffered from stress related to the pandemic and the lockdown measures put in place to contain the spread of the virus, the data showed. Advertisement Just under 12% indicated that they have contemplated suicide since the start of the pandemic, the researchers said. Although most of those who reported mental health problems related to the global crisis had a history of "psychiatric" diagnoses, more than 15% of them did not, according to the researchers. "These findings underscore the broad impact that the pandemic ... has had on peoples' lives," study co-author ...
Brain stimulation may reduce depression and PTSD symptoms, study says

Brain stimulation may reduce depression and PTSD symptoms, study says

Health
Dec. 21 (UPI) -- Applying small amounts of electricity to the brain can help reduce "negative emotions" in people with post-traumatic stress disorder and depression, according to a study published Monday by JNeurosci. The technique, called transcranial magnetic stimulation, or TMS, uses a changing magnetic field to target small electrical currents to a specific area of the brain -- in this case, the prefrontal cortex, the researchers said. Advertisement The prefrontal cortex, situated near the front of the brain, governs behavior, emotions and decision-making, among other functions, research suggests. Wearable devices using TMS have been used to treat migraines and other brain disorders, according to researchers from Shenzhen University in China. In addition, the U.S. Food and Drug Admini...
Childhood depression closely linked to diseases, early death, study says

Childhood depression closely linked to diseases, early death, study says

Health
Dec. 9 (UPI) -- Children with depression are at significantly increased risk for diseases linked to mental health issues and early death, according to a study published Wednesday by JAMA Psychiatry. The analysis of more than a million people treated in Sweden for depression as children found that men and women who were depressed during their youth were six times as likely to die at a young age, the data showed. Advertisement In addition, childhood depression suffers had an eight times higher risk for developing sleep disorders in adulthood, according to the researchers. This could include trouble sleeping or excessive daytime sleepiness, a disorder that causes sufferers to fall asleep during daytime hours, the researchers said. "Depressed children and teenagers have an increased risk of ...
Esketamine spray for treating depression ‘not cost-effective’

Esketamine spray for treating depression ‘not cost-effective’

Health
A nasal esketamine spray for hard-to-treat depression has been rejected for use on the NHS for a second time because of uncertainty over cost.Despite a need for new treatments for adults, it is also not clear how well the drug works long term, the healthcare watchdog NICE said.Esketamine is a form of ketamine that targets a chemical linked with learning and memory.The treatment was first rejected in January by NICE.Following comments by experts and clinicians, a second consultation on the draft guidance for England and Wales has now been launched.The nasal spray, which contains esketamine and is also called Spravato and made by Janssen, costs about £10,000 per course of therapy.In the US, it was approved for sale last year as a treatment for depression de...